Increasing Access to Fertility Preservation for Women with Breast Cancer

Summary

The EVAPREF project aims to increase access to fertility preservation by developing an approach to improve and evaluate existing information and coordination tools developed by the Pays-de-la-Loire and Occitanie Regional Cancer networks. First, the investigators will use a qualitative, iterative, user-centered and participatory approach to improve the current tools and create training content for the physicians who will use these tools. Second, the investigators will conduct a randomized stepped wedge trial of women under 40 newly treated with chemotherapy for breast cancer. The investigators will evaluate the rate of fertility preservation consultation before and after implementation of the improved tools, over a 30-month period from mid-2023 to the end of 2025. Finally, in a third step, the investigators will study their approach (context-sensitive implementation analysis) and provide key elements for its transferability to other contexts and in particular to other Regional Cancer networks in France.

Conditions

• Breast Cancer

Interventions

BEHAVIORAL

Informational brochure for patients and brief training for oncologists

For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.

Sponsors & Collaborators

• National Cancer Institute, France

  collaborator OTHER_GOV

• Institut Claudius Regaud

  collaborator OTHER

• Réseau Onco-Occitanie

  collaborator UNKNOWN

• Réseau ONCOPL

  collaborator UNKNOWN

• University Paul Sabatier of Toulouse

  lead OTHER

Principal Investigators

• Marie-Anne Durand, PhD · Université Toulouse III Paul Sabatier

Study Design

Allocation

RANDOMIZED

Purpose

OTHER

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

40 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-06-01

Primary Completion

2025-12-31

Completion

2026-12-31

Countries

• France

Study Locations